Medistem Laboratories Announces Epigenetic Collaboration With Albert Einstein College of Medicine and Kansas City Veterans Administration

Studies to Unveil Molecular Signature of Endometrial Regenerative Cells

Medistem Laboratories, Inc. (OTCBB: MDSM) (Medistem), Albert Einstein College of Medicine, Bronx, NY, and the Kansas City Veterans Administration (VA) announced a collaborative effort to characterize the epigenetic profile of Endometrial Regenerative Cells (ERC), Medistem's novel population of stem cells derived from the menstrual blood. The study will be led by the VA's Suman Kambhampati, MD, Albert Einstein's Amit Verma, MD and Medistem's CEO, Thomas Ichim, PhD.

Medistem's CEO, Thomas Ichim, commented, "The group assembled by Dr. Kambhampati is internationally recognized in the area of unraveling molecular signatures of various stem cell types in healthy and diseased conditions. Defining the unique subcellular characteristics that allow the ERC population to mediate its therapeutic properties will position Medistem to rapidly translate our in vitro and animal studies into human trials."

VA's Dr. Kambhampati stated, "Medistem's science-focused development strategy is apparent from their nine peer reviewed publications covering stem cell immunology, differentiation, and novel uses. We are enthusiastic about contributing to the critical mass of scientific collaborators that Medistem has assembled in developing its universal donor endometrial regenerative cell stem cell product."

"Researchers at Albert Einstein College of Medicine have developed a novel high through put assay to analyze genome-wide methylation that has been successfully used in cellular systems," said Dr. Amit Verma. "Leveraging this technology will position us to elucidate molecular mechanisms by which the Endometrial Regenerative Cell population produce such diverse biological effects."

About Kansas City Veterans Administration Medical Center

The Kansas City Veterans Administration Medical Center (http://www.kansascity.va.gov/) is a major center for research in the Midwest and conducts basic and clinical research in all major fields of study. The Center has 170 ongoing research projects and a long history of participation in VA Cooperative Group Studies with seminal involvement in studies that first described the efficacy of aspirin in ischemic heart disease.

About Albert Einstein College of Medicine

Albert Einstein College of Medicine (http://www.aecom.yu.edu/) is an NCI recognized Comprehensive Cancer Center that is one of the nation's premier institutions for medical education, basic research and clinical investigation. It is home to some 2,000 faculty members, 750 M.D. students, and 350 Ph.D. students.

About Medistem Laboratories, Inc.

Medistem Laboratories (www.medisteminc.com) is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. A peer reviewed publication describing this novel cell type may be found at http://www.translational-medicine.com/content/5/1/57. The company is currently focusing on use of endometrial regenerative cells for treatment of critical limb ischemia, an advanced form of peripheral artery disease that causes approximately 160,000 amputations per year.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.